ACM
PRAX icon

Accent Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Accent Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7K Hold
50
– – 0.01% 168
2026
Q1 		$16.1K Hold
50
– – 0.01% 163
2025
Q4 		$14.7K Buy
+50
New +$9.31K 0.01% 161

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Accent Capital Management's PRAX Position: Q2 2026 in Review

Accent Capital Management held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 50 shares worth $16.7K. The position accounts for 0.01% of the portfolio, ranked #168.

Accent Capital Management first reported a position in PRAX in Q4 2025 and has held it in 3 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Accent Capital Management held 50 shares of Praxis Precision Medicines worth $16.7K as of Q2 2026.
  • Accent Capital Management left its Praxis Precision Medicines share count unchanged in Q2 2026.
  • Praxis Precision Medicines made up 0.01% of Accent Capital Management's portfolio in Q2 2026, its #168 holding.
  • Accent Capital Management first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 3 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.